Worth Watching: Does Cerus Corporation Have Any Gas After Today’s Significant Increase?

Worth Watching: Does Cerus Corporation Have Any Gas After Today's Significant Increase?

The stock of Cerus Corporation (NASDAQ:CERS) is a huge mover today! About 2.94M shares traded hands or 270.00% up from the average. Cerus Corporation (NASDAQ:CERS) has declined 31.38% since April 4, 2016 and is downtrending. It has underperformed by 32.47% the S&P500.
The move comes after 9 months positive chart setup for the $476.67M company. It was reported on Nov, 4 by Barchart.com. We have $6.78 PT which if reached, will make NASDAQ:CERS worth $176.37 million more.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Out of 2 analysts covering Cerus (NASDAQ:CERS), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Cerus has been the topic of 3 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Thursday, December 17 by Wedbush. The stock has “Buy” rating given by Zacks on Tuesday, August 11. As per Wednesday, August 19, the company rating was maintained by BTIG Research.

According to Zacks Investment Research, “Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company’s initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.”

Insitutional Activity: The institutional sentiment decreased to 1.69 in 2016 Q2. Its down 0.06, from 1.75 in 2016Q1. The ratio worsened, as 10 funds sold all Cerus Corporation shares owned while 26 reduced positions. 8 funds bought stakes while 53 increased positions. They now own 66.39 million shares or 1.07% more from 65.69 million shares in 2016Q1.
The Washington-based Lesa Sroufe And Co has invested 3.33% in Cerus Corporation (NASDAQ:CERS). Primecap Ca reported 7.80 million shares or 0.05% of all its holdings. Tiaa Cref Invest Mngmt Limited Liability accumulated 440,105 shares or 0% of the stock. Moreover, Da Davidson And has 0.02% invested in Cerus Corporation (NASDAQ:CERS) for 122,710 shares. Paloma Prns Com has invested 0.01% of its portfolio in Cerus Corporation (NASDAQ:CERS). Turner Limited Partnership holds 0.12% or 60,000 shares in its portfolio. Pier Capital last reported 1.02% of its portfolio in the stock. Nationwide Fund owns 66,092 shares or 0% of their US portfolio. Bamco Inc Ny owns 81,000 shares or 0% of their US portfolio. Fmr Lc, a Massachusetts-based fund reported 940,617 shares. The Arkansas-based Stephens Ar has invested 0.39% in Cerus Corporation (NASDAQ:CERS). Parametric Portfolio Lc holds 0% or 69,943 shares in its portfolio. State Street accumulated 0% or 1.64M shares. Bank Of America Corporation De holds 0% or 563,923 shares in its portfolio. Grp Incorporated One Trading L P has 0.01% invested in the company for 82,037 shares.

Insider Transactions: Since August 22, 2016, the stock had 0 buys, and 1 sale for $116,612 net activity. Green Kevin Dennis also sold $116,612 worth of Cerus Corporation (NASDAQ:CERS) shares.

More recent Cerus Corporation (NASDAQ:CERS) news were published by: Businesswire.com which released: “Cerus Corporation Reports Third Quarter 2016 Results” on November 03, 2016. Also Fool.com published the news titled: “Cerus Corporation is Surging Today. Here’s Why.” on June 20, 2016. Benzinga.com‘s news article titled: “Mid-Morning Market Update: Markets Open Lower; Humana Beats Q3 Estimates” with publication date: November 04, 2016 was also an interesting one.

CERS Company Profile

Cerus Corporation, incorporated on July 31, 1996, is a biomedical products company. The Firm is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Firm operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment